Avicenna Alliance: enhanced knowledge, improved decisions, better outcomes
FULL MENU

News

News EMA PRIME scheme – room for improvement

EMA PRIME scheme – room for improvement

On 07 March 2016, the European Medicines Agency (EMA) launched their new Priority Medicines Scheme (PRIME) which aims to accelerate assessment of innovative medicines by shortening development time through stronger interactions between industry and the EMA. The scheme has a good number of similarities (at least in terms of goals) as the FDA designed “Innovative Pathway 2.0” which also aims to tackle the long time to market of new therapies.

News Over the Horizon 2020

Over the Horizon 2020

Ignoring the painfully unimaginative title of this article and getting to substance, the planning for the successor to Horizon 2020 is to start soon. This is no small task and to see how the 9th Framework Programme for Research and Innovation might turn out, it is worth having a look at why Horizon 2020 was brought in to replace FP7.

News Avicenna Alliance proclaims victory in EMA Regulation

Avicenna Alliance proclaims victory in EMA Regulation

The Avicenna Alliance, can claim a major victory in the revised EMA Regulation with the introduction of new text supporting modelling and simulation and predictive medicine in medicinal product development.

News EMA Regulation amendments call for framework for in silico

EMA Regulation amendments call for framework for in silico

Amendments calling for the creation of a framework for in silico medicine have been tabled by MEP Martin Häusling (Greens/EFA, Germany) to the EMA Regulation Report by Claudiu Ciprian Tănăsescu (S&D, Romania). This report, currently being discussed by the European Parliament’s Environment, Public Health and Food Safety Committee (ENVI) Committee would amend the 2004 EU Regulation on the placing on the market of medicinal products and the establishment of a European Medicines Agency.

News US Legislature says FDA should use in silico methods

US Legislature says FDA should use in silico methods

In an unprecedented victory for the in silico community in the US Congress has put forward a bill that “urges FDA to engage with device and drug sponsors to explore greater use, where appropriate, of In Silico trials for advancing new devices and drug therapy applications.”

Sign up for our monthly newsletter!

Sign up for our monthly newsletter!

Fill in the fields you find below

Avicenna Alliance is an initiative of:

Avicenna VPH

© 2018-2024 Avicenna Alliance | powered by We Berry